Showing 3871-3880 of 5773 results for "".
- Santen Launches Eyecare Education Learning Portal for Ophthalmologists in Europehttps://modernod.com/news/santen-launches-eyecare-education-learning-portal-for-ophthalmologists-in-europe/2480651/Santen announced
- Elios Reports 8-Year Results of its Excimer Laser Trabeculostomy Procedure Combined With Cataract Surgeryhttps://modernod.com/news/elios-reports-8-year-results-of-its-excimer-laser-trabeculostomy-procedure-combined-with-cataract-surgery/2480650/Elios Vision announced 8-year follow up results of its Elios Excimer Laser Trabeculostomy procedure combined with cataract surgery. According to Elios, key finding of the study include: 161 eyes of 128 patients with glaucoma or ocular hypertension and cataract rec
- Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucomahttps://modernod.com/news/sight-sciences-launches-dont-wait-for-too-late-awareness-campaign-for-glaucoma/2480649/Sight Sciences announced the launch of its “Don’t Wait for Too Late” educational campaign designed to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma.
- New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with Tepezza Comparable with Clinical Trial Observationshttps://modernod.com/news/new-post-marketing-safety-analysis-shows-rate-of-hearing-related-events-associated-with-tepezza-comparable-with-clinical-trial-observations/2480647/Horizon Therapeutics announced results from a new post-marketing safety analysis of hearing events associated with Tepezza for the treatment of Thyroid Eye Disease (TED). These findings, along with data on the sustainability of response to Tepezza, were presented at the 48th
- SIFI Provides Regulatory Updates for Akantior (Polihexanide 0.8 mg/ml) in Europe and the United Stateshttps://modernod.com/news/sifi-provides-regulatory-updates-for-akantior-polihexanide-08-mgml-in-europe-and-the-united-states/2480643/SIFI announced the accomplishment of several ta
- Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conferencehttps://modernod.com/news/clearside-biomedicals-suprachoroidal-injection-platform-featured-at-the-angiogenesis-exudation-and-degeneration-2022-virtual-conference/2480642/Clearside Biomedical announced that multiple oral presentations on Clearside’s SCS injection platform featuring the SCS Microinjector were given at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event held February 11-12,
- Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022https://modernod.com/news/opthea-data-for-opt-302-in-patients-with-polypoidal-choroidal-vasculopathy-pcv-presented-at-angiogenesis-2022/2480640/Opthea announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The presentation, entitled “OPT-302 Combination Therapy with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy,&r
- Regenxbio Presents Positive Interim Data From Phase 2 ALTITUDE Trial of RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-presents-positive-interim-data-from-phase-3-altitude-trial-of-rgx-314-for-treatment-of-diabetic-retinopathy-using-suprachoroidal-delivery/2480639/Regenxbio announced additional positive interim data from the ongoing phase 2 ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data is being presented at the Angiogene
- Regeneron Presents Encouraging Phase 2 Results for High-Dose Aflibercept 8 mg in Wet AMDhttps://modernod.com/news/regeneron-presents-encouraging-phase-2-results-for-high-dose-aflibercept-8-mg-in-wet-amd/2480636/Regeneron Pharmaceuticals announced results from its phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 mg dose of Eylea (aflibercept) Injection in patients with wet age-related macular degeneration (AMD). The resul
- Euclid Systems Expands US Commercial Teamhttps://modernod.com/news/euclid-systems-expands-us-commercial-team/2480634/Euclid Systems has announced the expansion of its US commercial team with the addition of Kellie Wesley, who has joined the com